Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells
- PMID: 14702634
- DOI: 10.1038/nm976
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells
Erratum in
- Nat Med. 2004 Feb;10(2):209
Abstract
Although tumor progression involves processes such as tissue invasion that can activate inflammatory responses, the immune system largely ignores or tolerates disseminated cancers. The mechanisms that block initiation of immune responses during cancer development are poorly understood. We report here that constitutive activation of Stat-3, a common oncogenic signaling pathway, suppresses tumor expression of proinflammatory mediators. Blocking Stat-3 in tumor cells increases expression of proinflammatory cytokines and chemokines that activate innate immunity and dendritic cells, leading to tumor-specific T-cell responses. In addition, constitutive Stat-3 activity induces production of pleiotropic factors that inhibit dendritic cell functional maturation. Tumor-derived factors inhibit dendritic cell maturation through Stat-3 activation in progenitor cells. Thus, inhibition of antitumor immunity involves a cascade of Stat-3 activation propagating from tumor to dendritic cells. We propose that tumor Stat-3 activity can mediate immune evasion by blocking both the production and sensing of inflammatory signals by multiple components of the immune system.
Similar articles
-
Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects.J Immunol. 2005 Apr 1;174(7):3925-31. doi: 10.4049/jimmunol.174.7.3925. J Immunol. 2005. PMID: 15778348 Free PMC article.
-
Characterization of the roles of STAT1 and STAT3 signal transduction pathways in mammalian lens development.Mol Vis. 2004 Feb 19;10:122-31. Mol Vis. 2004. PMID: 14978477
-
Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells.Oncogene. 2001 May 3;20(20):2499-513. doi: 10.1038/sj.onc.1204349. Oncogene. 2001. PMID: 11420660
-
Targeting the STAT pathway in head and neck cancer: recent advances and future prospects.Curr Cancer Drug Targets. 2004 Dec;4(8):637-51. doi: 10.2174/1568009043332736. Curr Cancer Drug Targets. 2004. PMID: 15578920 Review.
-
Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention.Clin Cancer Res. 2002 Apr;8(4):945-54. Clin Cancer Res. 2002. PMID: 11948098 Review.
Cited by
-
Immune Profiling Reveals Molecular Classification and Characteristic in Urothelial Bladder Cancer.Front Cell Dev Biol. 2021 Mar 11;9:596484. doi: 10.3389/fcell.2021.596484. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 33777927 Free PMC article.
-
Kaposi's sarcoma-associated herpesvirus kaposin B induces unique monophosphorylation of STAT3 at serine 727 and MK2-mediated inactivation of the STAT3 transcriptional repressor TRIM28.J Virol. 2013 Aug;87(15):8779-91. doi: 10.1128/JVI.02976-12. Epub 2013 Jun 5. J Virol. 2013. PMID: 23740979 Free PMC article.
-
Genomic Alterations and Their Implications on Survival in Nonmetastatic Colorectal Cancer: Status Quo and Future Perspectives.Cancers (Basel). 2020 Jul 22;12(8):2001. doi: 10.3390/cancers12082001. Cancers (Basel). 2020. PMID: 32707813 Free PMC article. Review.
-
Prognostic significance of B-cells and pSTAT3 in patients with ovarian cancer.PLoS One. 2013;8(1):e54029. doi: 10.1371/journal.pone.0054029. Epub 2013 Jan 10. PLoS One. 2013. PMID: 23326565 Free PMC article.
-
Exploring Novel Frontiers: Leveraging STAT3 Signaling for Advanced Cancer Therapeutics.Cancers (Basel). 2024 Jan 24;16(3):492. doi: 10.3390/cancers16030492. Cancers (Basel). 2024. PMID: 38339245 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous